Table 3 Comparison of transplant-related outcomes of patients with t-APL vs. de novo APL.
Characteristics | t-APL (n = 20) | De novo APL (n = 124) | P |
|---|---|---|---|
Engraftment failure, n (%) | 1 (5) | 1 (0.8) | 0.259 |
Secondary graft failure, n (%) | 0 | 3 (2) | 0.999 |
Neutrophil engraftment, median (range) days | 17 (9–29) | 17 (9–35) | 0.663 |
Cumulative incidences (95% CI) of neutrophil engraftment at 35 days, % | 95.0 (79.4–99.7) | 99.1 (95.9–99.9) | 0.835 |
Cumulative incidences (95% CI) of grades II-IV acute GVHD at 100 days, % | 20.7 (8.2–46.3) | 43.3 (35.0–53.5) | 0.070 |
Onset of grades II-IV acute GVHD, median (range), day | 16 (12–41) | 21 (6–111) | 0.645 |
Cumulative incidences (95% CI) of chronic GVHD at 1 year, % | 46.1 (26.1–71.7) | 34.6 (26.0–45.1) | 0.460 |
Onset of chronic GVHD, median (range), day | 124 (84–248) | 101 (42–1158) | 0.353 |
Secondary solid malignancies, n (%) | 0 | 4 (3) | 0.999 |
Cumulative incidences (95% CI) of relapse at 5 years after HCT, n (%) | 42.5 (23.7–67.8) | 39.0 (30.4–49.1) | 0.583 |
Cumulative incidences (95% CI) of TRM at 5 years after HCT, % | 17.3 (5.9–44.8) | 25.0 (17.8–34.6) | 0.582 |
Median (range) follow-up of survivors, mo | 114 (16–173) | 87 (3–167) | 0.512 |
Cause of death, n (%) APL | 5 (25) | 30 (24) | 0.374 |
 Infection | 2 (10) | 14 (11) |  |
 Organ failure | 1 (5) | 7 (6) |  |
 GVHD | 1 (5) | 4 (3) |  |
 NRM | 2 (10) | 13 (10) |  |
